We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases (cancer, neuromuscular disease and infectious diseases) with high unmet medical need. Exosomes are intercellular transfer mechanisms; they have emerged in recent years as a compelling potential drug delivery vehicle.

There have been no approved exosome-based therapeutics to date.

Our lead product candidates are being developed to treat solid tumors. We expect to enter clinical trials in the second half of 2020.